Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $83M (up 38.3% year over year) with net income of $2M.
Q1 2026 key financials · XBRL
- Revenue
- $83M
- +38.3% YoY
- Net income
- $2M
- +124.2% YoY
- Operating margin
- 9.5%
- EPS (diluted)
- $0.01
- +116.7% YoY
Source: XBRL data from the Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 10-Q on SEC EDGAR. USD.
Xeris Biopharma Holdings, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Investing cash use $325 thousand vs $13 thousand YoY, driven by higher capital expenditures
- Financing cash use $8.8 million vs $3.1 million YoY
- Stock-tax withholding repurchases $17.0 million vs $8.0 million YoY
- Stock-award and warrant proceeds $8.2 million vs $4.9 million from stock awards YoY
Risk Factors
- No material changes to risk factors since December 31, 2025 Form 10-K
- No newly added risk factor or triggering event disclosed for quarter ended March 31, 2026
- Carried-forward regulatory, legal, and compliance risks remain unchanged from the 2025 Form 10-K
- Carried-forward operational, competitive, market, and financial risks remain unchanged from the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xeris Biopharma Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.